相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells
Mitsuki Tabata et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (Pom-PAD-Dara) in relapsed/refractory multiple myeloma
Xiang Zhou et al.
CANCER MEDICINE (2020)
Current Treatment Strategies for Multiple Myeloma
Andrew Branagan et al.
JCO ONCOLOGY PRACTICE (2020)
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Taylor Harding et al.
LEUKEMIA (2019)
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model
Claudia Christowitz et al.
BMC CANCER (2019)
Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
Phuong Nguyen et al.
FRONTIERS IN ONCOLOGY (2019)
Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells
Jahangir Abdi et al.
BMC CANCER (2019)
Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
Masanobu Tsubaki et al.
CANCERS (2019)
RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells
Keiji Mashimo et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2019)
Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB
Masanobu Tsubaki et al.
LABORATORY INVESTIGATION (2019)
The MIP-1 autocrine loop contributes to decreased sensitivity to anticancer drugs
Masanobu Tsubaki et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPAR-independent pathway
Masanobu Tsubaki et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
A. Besse et al.
LEUKEMIA (2018)
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin et al.
BLOOD (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer
Jiahui Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
The molecular mechanisms of chemoresistance in cancers
Hua-Chuan Zheng
ONCOTARGET (2017)
Myeloma today: Disease definitions and treatment advances
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Connor P. Hall et al.
CLINICAL CANCER RESEARCH (2016)
MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy
Anna Polak et al.
PLOS ONE (2016)
RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines
Masanobu Tsubaki et al.
TUMOR BIOLOGY (2016)
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma
Hua Yang et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)
Microenvironment drug resistance in multiple myeloma: emerging new players
Lucia Di Marzo et al.
ONCOTARGET (2016)
BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance
Yun Dai et al.
AUTOPHAGY (2015)
Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein
Tomohiro Nabekura et al.
BIOMEDICINE & PHARMACOTHERAPY (2015)
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Michael R. Clemens et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-Small-Cell Lung Cancer A Randomized Open-Label Phase II Study
Ronald Natale et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
By inhibiting Sic, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells
Masanobu Tsubaki et al.
LEUKEMIA RESEARCH (2014)
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
Bruce D. Cheson et al.
CANCER (2012)
Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells
Masanobu Tsubaki et al.
LEUKEMIA RESEARCH (2012)
Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells
Nuria Lopez-Royuela et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
Jose A. Richter-Larrea et al.
BLOOD (2010)
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
Elke De Bruyne et al.
BLOOD (2010)
IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
Yasunori Nakagawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (Valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) - A Trial of the Eastern Cooperative Oncology Group
WR Friedenberg et al.
CANCER (2006)
分享论文
